An oral formulation of amphotericin B attached to functionalized carbon nanotubes is an effective treatment for experimental visceral leishmaniasis.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 22158723.
- Also identified by DOI 10.1093/infdis/jir735 and PMC identifier 3244370.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Amphotericin B (AmB), is a highly effective antileishmanial agent used as first-line treatment in different formulations in visceral leishmaniasis endemic areas of Bihar, India. However, parenteral infusion, prolonged hospitalization, and toxicity are major hurdles. Our previous work demonstrated the efficacy and stability of functionalized carbon nanotubes as a delivery mechanism for AmB. In this study, using the hamster model, we have shown that this novel formulation of AmB can be administered orally, resulting in 99% inhibition of parasite growth following a 5-day course at 15 mg/kg body weight.
Medical subject headings
- Amphotericin B
- Antiprotozoal Agents
- Leishmania donovani
- Leishmaniasis, Visceral
- Nanotubes, Carbon
- Splenic Diseases